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Abstract
Background: Cancer is commonly associated with widespread disruption of DNA methylation, chromatin
modification and miRNA expression. In this study, we established a robust discovery pipeline to identify
epigenetically deregulated miRNAs in cancer.
Results: Using an integrative approach that combines primary transcription, genome-wide DNA methylation and
H3K9Ac marks with microRNA (miRNA) expression, we identified miRNA genes that were epigenetically modified in
cancer. We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically
activated in prostate cancer cells.
Conclusions: We show that detecting changes in primary miRNA transcription levels is a valuable method for
detection of local epigenetic modifications that are associated with changes in mature miRNA expression.
Background
MiRNA genes are typically transcribed by RNA poly-
merase II into primary miRNA (pri-miRNA) transcripts,
and transcription appears to be regulated in a similar
process as traditional coding genes [1]. Pri-miRNA tran-
scripts are long non-coding RNAs (ncRNA) with stem-
loop secondary structures that contain precursor miR-
NAs (pre-miRNA). Pri-miRNA transcripts are cleaved
co-transcriptionally by the enzyme Drosha into stem
loop pre-miRNAs, which are exported to the cytoplasm
by Exportin 5, and further processed by Dicer into
mature miRNA that can be loaded in the RNA induced
silencing complex (RISC). Pre-miRNA levels are low
relative to pri- and mature miRNAs, suggesting that
dicing is an efficient mechanism with little regulation
[2]. During development, many pri-miRNAs are
expressed but not efficiently processed to mature
miRNA [3]. In healthy tissues, the ratio of pri- to
mature miRNAs has been shown to be close to one,
while in cancer cells, a large number of miRNA genes
are transcribed but not processed to mature miRNA [4].
An expanding body of evidence supports a role for
miRNAs in disease progression and the potential for
epigenetic mechanisms to regulate miRNA expression
[5,6]. Epigenetics is the heritable modification of gene
expression without changes in the DNA sequence. The
importance of regulated epigenetic information is high-
lighted by the disruption of multiple epigenetic marks in
various disease states, including cancer, which is com-
monly associated with deregulation of DNA methylation,
histone modifications and miRNA expression [7]. Cyto-
sine methylation of CpG islands associated with gene
promoters is a well-studied epigenetic mark, and aber-
rant DNA hypermethylation in combination with altered
histone architecture is a common hallmark of neoplastic
cells [8]. Histone acetylation at lysine 9 (H3K9Ac) is
associated with an active chromatin state and changes in
its global patterning are linked to poor prognosis in
multiple cancers [9]. MiRNAs have been shown to func-
tion as tumor suppressors and oncogenes, through the
targeting of essential elements of cellular growth, prolif-
eration and apoptotic pathways [10]. Genomic loci
encoding miRNAs can become epigenetically remodelled
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changes in cancer remains to be elucidated [6].
We argue that a minority of miRNA genes, critical to
regulation of cellular growth, proliferation, or survival,
gain epigenetic modifications to enable persistent
enhancement or inhibition of their activity in order to
maintain a neoplastic phenotype. Using an integrative
approach combining primary transcription, genome-
wide DNA methylation and H3K9Ac patterns with
mature miRNA levels, we identified a number of
miRNA genes that showed epigenetic remodeling in
cancer in combination with de-regulation of both the
primary and mature miRNA. This demonstrates that
integration of multiple methods of analysis may provide
a reliable method for the identification of epigenetically
regulated miRNAs.
Results and Discussion
We proposed that epigenetically de-regulated miRNAs
in cancer would show three characteristics: first, differ-
ential expression at the primary transcript level, second,
differential mature miRNA expression, and finally an
associated change in one or more epigenetic marks. To
eliminate post-transcriptionally regulated miRNAs that
showed accumulation of epigenetic marks independent
of their transcription, an integrative pipeline that
assessed all three criteria was developed (Figure 1).
Normal prostate epithelial (PrEC) and prostate cancer
(LNCaP) cells were used as a model system to test this
integrative pipeline in the discovery of epigenetically
de-regulated miRNAs in cancer. Custom high-density
NimbleGen tiling arrays covering miRNA loci from
miRBase v12.0 were designed and used to probe total
RNA to determine transcription levels, and DNA from
methylated-DNA immunoprecipitation (MeDIP) and
H3K9Ac immunoprecipitation to investigate epigenetic
changes. The oligonucleotide probes of these arrays
have an average length of 60nt, precluding interference
of the mature 20-23nt miRNAs, thus assaying the full-
length primary transcripts. Plotting the array probe
intensities against chromosomal coordinates generated
high-resolution maps of expression and epigenetic mark
enrichment across each locus (plots for miR-205 are
shown in Figure 1A &1B as examples). To generate lists
of loci significantly changed in LNCaP cells for each
assay, we selected those that were consistently changed
in the cancer cell line within 500 bp of the center of the
miRNA gene. For our comparisons, we limited the num-
ber of miRNAs to those that were assayed by both
TaqMan
® Low Density Arrays (TLDA) (Figure 1C) and
tiling array: 341 miRNAs in total. All changes are articu-
lated as LNCaP with respect to PrEC.
Looking at those loci whose primary transcript repres-
sion or activation in LNCaP was associated with a
significant change in the mature miRNA, we identified 29
upregulated and 33 downregulated miRNAs (Figure 2A,B).
We then looked for concomitant epigenetic changes at
these loci in the tiling array data. A high proportion of the
upregulated (31%; 9/29) and downregulated loci (33%;
11/33) showed an overlap with at least one of these epige-
netic marks (Figure 2C,D). The majority (18/20) of these
miRNAs have previously been identified as deregulated in
various cancers, and five with prior evidence for epigenetic
regulation (Table 1). A concordant change in all assays;
expression, DNA methylation, and H3K9Ac restricted the
total number of candidate miRNAs to 2/29 up- and 4/33
downregulated (Figure 2C,D). Given the large number of
possible epigenetic modifications (for a recent review see
[6]), it is possible that many of the differentially expressed
loci that show no change in DNA methylation or H3K9Ac
could undergo changes in other epigenetic marks. Further-
more, miRNAs may be regulated by DNA methylation at
CpG islands outside the 2000 bp regions interrogated in
this analysis.
In order to perform an independent test for miRNAs
regulated by DNA methylation, we treated LNCaP and
PrEC cells with the drug 5-Aza-CdR, an inhibitor of
DNA methylation, and analysed their expression by
TLDA. Restricting our list to miRNAs that were signif-
icantly deregulated between PrEC and LNCaP we
found 30 upregulated by 5-Aza-CdR in PrEC and 16 in
LNCaP. Of the miRNA loci showing epigenetic activa-
tion by the three criteria of primary transcript expres-
sion, DNA methylation loss and H3K9Ac gain, only
miR-615 showed 5-Aza-CdR induced reactivation in
the normal prostate PrEC cells (Figure 2E). MiR-205,
miR-196b and miR-21 satisfied all three criteria for
epigenetic repression, and LNCaP 5-Aza-CdR reactiva-
tion (Figure 2F).
MiRNA genes showing non-canonical epigenetic regu-
lation were also observed. That is, miRNAs showing up
regulation of primary and mature miRNA expression,
with a concomitant gain of DNA methylation or loss of
H3K9Ac, or vice versa. Twelve miRNAs showed activa-
tion and gain of repressive epigenetic marks and six
(including the chromosome 14 miRNA cluster) showed
repression in combination with active chromatin (Addi-
tional file 1, Table S1). None of these miRNAs showed
significant up regulation upon treatment with 5-Aza-
CdR. Several miRNAs were repressed in the presence of
the demethylating drug, suggesting the repression of
these loci may be dependent on genes that are them-
selves subject to regulation by DNA methylation.
To validate the changes in primary miRNA expression,
we performed pri-miRNA TaqMan
® qPCR on the four
miRNAs that met all our criteria. These assays con-
firmed the repression of pri-miR-205 and pri-miR-21,
and over expression of pri-miR-615 in LNCaP cells
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Page 2 of 9(Figure 3A,B,D). There was no significant change in pri-
miR-196b between LNCaP and PrEC, however treat-
ment with 5-Aza-CdR led to overexpression in PrEC
cells (Figure 3C). 5-Aza-CdR led to overexpression of
pri-miR-21 and pri-miR-615 in LNCaP, as would be pre-
dicted by their DNA methylation status (Figure 3B,D).
However, reactivation of pri-miR-205 by 5-Aza-CdR was
not significant (Figure 3A).
To verify changes in DNA methylation we analysed
recently published methyl-CpG binding domain-based
capture (MBDCap) data from LNCaP and PrEC cells
[11]. MBDCap preferentially captures DNA methylated
double-stranded DNA which is then eluted for high-
throughput sequencing [12]. We examined the number
of sequencing reads that mapped to within 300 bp of
the selected miRNA loci. In agreement with the tiling
Figure 1 Schematic displaying experimental discovery pipeline used for identification of miRNAs epigenetically deregulated in cancer.
To identify epigenetically regulated miRNAs, we employed an integrative approach assessing changes in epigenetic marks, primary miRNA
transcript, and mature miRNA. (A, B) Custom tiling arrays probing all miRNA loci (miRBase12.0, 668 miRNA loci) were used to assay primary
miRNA transcription and epigenetic marks (H3K9Ac and DNA methylation) from PrEC and LNCaP cells. Example tiling array intensity plots are
shown of the 2000 bp region spanning the miR-205 gene for both expression (A), and DNA methylation (B), showing the chromosomal
coordinate (x-axis) and the hybridization intensity (y-axis), with regions displaying significant differences highlighted. (C) Global mature miRNA
expression levels in PrEC and LNCaP cells +/- 5-Aza-CdR treatment (3 μM LNCaP, 1 μM PrEC; 72 hours) as determined by TLDA qRT-PCR (368
miRNAs).
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Page 3 of 9Figure 2 Progressive steps in the identification of epigenetically regulated miRNAs in prostate cells. Venn diagrams show the number of
miRNA loci changed in LNCaP (L) with respect to PrEC (P) cells called significant by tiling arrays analysis using a t-statistic ≤-2 or ≥2 for regions
+/-500 bp from the relevant miRNA. (A, B) Overlap of pri- and mature miRNA expression levels identified by tiling array and TLDA, respectively
(TLDA miRNA expression data was normalized to RNU48, using a significance cutoff at p < 0.05 and ≥1.5 -fold change). Concomitant changes in
active (H3K9Ac) or repressive (DNA methylation) epigenetic marks were then considered for miRNAs displaying significantly changed expression.
(C, D) miRNA loci significantly changed in MeDIP-chip and H3K9Ac ChIP-chip tiling array analysis. (E, F) Four-way Venn diagrams showing the
overlap of tiling array data with mature miRNA level upon 5-Aza-CdR treatment. MiR-615 lies at the four-way intersection indicating epigenetic
up-regulation and miR-205, miR-196b and miR-21 are at the intersection of epigenetic down-regulation in LNCaP cells.
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Page 4 of 9array data, there was enrichment of sequencing reads at
the MIR196b locus (Additional file 1, Figure S1).
MIR205 and MIR21 had increased reads in LNCaP over
PrEC, however there was also an increase in the input
DNA controls. MIR615 showed a low number of
sequencing events in both LNCaP and PrEC and input
controls (Additional file 1, Figure S1).
The identification of miR-205 as an epigenetically
repressed miRNA is consistent with a previous study
that examined chromatin modifications in prostate cells
using genome-wide promoter arrays, which revealed a
gain of the repressive H3K27-trimethylation mark and
loss of the active H3K4-trimethylation mark at the
MIR205 locus in prostate cancer cells [13]. Furthermore,
we recently reported that MIR205 locus is silenced and
gains promoter hypermethylation and repressive chro-
matin marks in invasive bladder tumors and undifferen-
tiated bladder cell lines [14]. Two expression array
studies have also identified miR-205 as repressed in
prostate cancer [15,16]. While the repression of pri-
miR-205 was validated by qPCR, the lack of significant
change in DNA methylation observed in the MBDCap
high-throughput sequencing data could be due to differ-
ences between the techniques. Both MIR205 and MIR21
reside in regions of low CpG density, whereas MIR196b
and MIR615 are located in regions of high CpG density,
which may bias the purification efficiencies. Variations
between pri-miRNA and array results, such as with pri-
miR196b, could be accounted for by differences in assay
design. An advantage of the tiling array approach is the
high-density coverage of all loci. PCR typically provides
improved dynamic range over array analysis, however,
the efficiency of a reaction can be limited by location of
the primers - as may be the case with pri-miRNA tran-
scripts that have yet to be exhaustively mapped. MiR-21
shows significant epigenetic repression in our array and
qPCR analyses, contradictory to its well-established role
as an oncogenic miRNA that is overexpressed in cancer
[17], however recent evidence has also shown that miR-
21 knockdown elicited no change in proliferative or
invasive properties in prostate cancer cells [18].
The potential for epigenetic regulation of MIR21 has
previously been shown in ovarian cancer, where treat-
ment with 5-Aza-CdR leads to miR-21 overexpression
[19], consistent with hypermethylation of the locus. It is
possible that epigenetic mechanisms may play a role in
context dependent regulation of miR-21 expression, and
it would be interesting to examine the prevalence of epi-
genetic marks at in a cohort of clinical prostate cancer
samples. The epigenetic regulation of both MIR615 and
MIR196b is particularly intriguing as both genes are
encoded from CpG islands located within HOX gene
Table 1 Candidate epigenetically regulated miRNAs
Tiling array Mature miRNA fold change Reference
Name Chr Str RNA DNA meth. H3K9Ac ChIP L v P p L v 5Aza p P v 5Aza p Epi./Cancer
MIRLET7c 21 + 34.26 -0.14 3.07 54.948 * 0.986 1.505 -/[33]
MIR141 12 + 7.2 -0.46 4.31 2.928 * 2.235 * 1.110 [34]
MIR15b 3 + 11.41 -4.65 -4.02 2.071 * 0.616 0.986 -/[35]
MIR16-2 3 + 10.52 -3.6 -2.54 2.713 * 1.424 * 0.742 -/[36]
MIR423 17 + 8.91 -0.81 2.39 4.857 * 0.774 2.445 * -/[37]
MIR491 9 + 9.03 -2.08 0.83 5.352 * 1.117 1.301 -/[38]
MIR615 12 + 4.03 -3.45 5.5 1.9E+03 * 1.231 32.672 * -/-
MIR618 12 - 4.18 2.44 5.73 4.1E+02 * 1.945 * 1.385 -/[39]
MIR99a 21 + 26.52 -2.9 3.72 2.329 * 1.035 0.908 -/[40]
MIR130a 11 + -7.19 -1.92 -3.85 0.004 * 2.532 * 1.102 -/[41]
MIR135b 1 - -3.93 2.8 -7.82 0.003 * 0.337 1.828 -/[42]
MIR137 1 - -3.81 1.19 -3.41 0.016 * 2.173 5.897 [43]
MIR196b 7 - -11.26 2.07 -5.05 0.356 * 1.591 * 0.829 [21]/[44]
MIR205 1 + -26.47 2.37 -12.09 1.2E-05 * 1.1E+02 * 1.659 [13]/[15]
MIR21 17 + -21.68 13.78 -12.98 0.637 * 2.362 * 3.272 * [19]/[18]
MIR24-1 9 + -5.64 3.73 -0.27 0.057 * 1.569 * 1.231 -/[45]
MIR31 9 - -2.79 -9.75 -3.04 1.7E-06 * 1.357 0.959 -/[46]
MIR376a-2 14 + -5.98 2.96 2.59 0.020 * 4.857 2.888 -/[47]
MIR424 X - -3.94 1.95 -2.56 0.259 * 0.883 4.287 * -/[39]
MIR654 14 + -5.42 2.57 4.14 0.136 * 1.357 0.295 * -/-
Table listing significantly changed miRNA genes identified in this study. Values represent relative change in LNCaP compared to PrEC. Tiling array t-statistics
represent the significance of the average difference for each miRNA, with increasing values indicating higher significance level. Mature miRNA levels are given as
-fold change with the associated p-value. The four miRNAs found to be significant in all our criteria are highlighted in bold type. Chr: Chromosome, Str: Strand,
meth: DNA-methylation, L: LNCaP, P: PrEC, 5Aza: treatment with 5-Aza-CdR, p *: p-value < 0.05, Epi./Cancer: publication indicating epigenetic/cancer regulation.
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methylated in acute lymphobla s t i cl e u k e m i a[ 2 0 ]a n d
gastric cancer [21] but to the best of our knowledge, the
epigenetic regulation of MIR615 is a novel discovery.
MIR615 is located within the HOXC cluster on chromo-
some 13, which we previously have shown to be epigen-
etically deregulated in LNCaP cells in long range
epigenetically silenced domains [22]. There is evidence
that HOX associated miRNAs are essential for develop-
ment and can function by targeting HOX messenger
RNAs [23]. Furthermore, HOX genes have been
reported to be involved in abnormal development and
malignancy in numerous cancers via both genetic and
epigenetic mechanisms [24].
There are inherent limitations to the various available
global epigenetic discovery techniques [11]. Immunopre-
cipitation based techniques can be affected by antibody
sensitivity and MeDIP can be biased towards regions of
high CpG content, leading to increased false-negatives
at GC-poor sites [25]. In addition, treatment with
demethylating drugs such as 5-Aza-CdR can uncover
false positives through activation or repression of
downstream targets [26]. A multi-platform approach can
help rule out many of these false positive results, but
the problem of false negatives remains. Here we show
that using miRNA primary transcript data enables lever-
age of the known mechanism of post-transcriptional
regulation of miRNAs as an additional means of epige-
netic marker discovery. Epigenetic marks such as DNA
methylation possess several advantages as biomarkers;
DNA is more robust than RNA, can be isolated from
formalin fixed paraffin-embedded archival samples and
DNA methylation provides a positive readout for genes
or miRNAs that are downregulated [27].
Conclusions
We found that up to 33% of transcriptionally deregu-
lated miRNA loci displayed concordant DNA methyla-
tion and H3K9 acetylation patterns. Extending the
analysis to additional epigenetic marks, such as the
methylation of H3K4, H3K9 and H3K27 and acetylation
at H3K14 will increase the number of identified loci.
The use of tiling arrays in this study enabled analysis
within 2000 bp of a miRNA gene and the increasing
Figure 3 Vailidation of pri-miRNA expression. Quantitative TaqMan
® RT-PCR of pri-miRNA expression in LNCaP and PrEC cells +/- 5-Aza-CdR
treatment (n = 6, +/-SD, *p <0.05). Pri-miRNA RT-PCR assays followed established TaqMan
® workflows (Applied Biosystems). Briefly, total RNA
was used for first-strand cDNA synthesis using 1 μg RNA Superscript reverse transcriptase (Invitrogen). cDNA was then subjected to 40 cycles of
amplification using an ABI7900 instrument (Applied Biosystems). Data was normalized to 18S levels (2
-dCt).
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Page 6 of 9availability of high-throughput sequencing technology
will allow this approach to be extended genome wide.
The prevalence of miRNAs that show contradicting
expression and epigenetic marks suggests that there is a
subset of genes that are subject to a complex pattern of
regulation, where specific marks may recruit activators
or repressors to a promoter. We propose that in cancer,
a change in primary transcript expression at miRNA
loci provides an important first step in the identification
of those miRNAs that display variant epigenetic marks.
Overlapping these loci with change in mature miRNA
restricts analysis to miRNAs that are functionally rele-
vant and that provide possible selective advantage to the
cancer cell. Further discovery of DNA hyper- and hypo-
methylated miRNAs in cancer using this type of integra-
tive discovery pipeline should assist in identifying loci
that may provide reliable novel diagnostic tools.
Methods
Cell Lines and Culture
LNCaP cells were propagated in T-media as described
previously [28]. PrEC cells were propagated in PrEGM
(Lonza, Switzerland). 5-Aza-2’-deoxycytidine (5-Aza-CdR)
(Fluka, MO, USA) treatment was performed for 72
hours with fresh media and drug added at 24 and 48
hours. We optimized 5-Aza-CdR treatment of LNCaP
and PrEC cells at 3 μMa n d1μM, respectively, based
on reactivation of the imprinted gene IGF2 and the
prostate cancer hypermethylated gene GSTP1 in
response to treatment, as described previously [28].
Total RNA was isolated using Trizol reagent according
to supplier’s protocol (Invitrogen, CA, USA). Genomic
DNA was extracted from untreated LNCaP and PrEC
using the Mammalian Blood and Tissue Kit (Qiagen,
Germany).
TaqMan
® Low-Density Arrays (TLDA)
TLDA v1.0 Early Access (Applied Biosystems, CA,
USA) assays for 368 miRNAs were performed as per
manufacturer’s protocols. In brief, 1 μgt o t a lR N A
from 5-Aza-CdR treated and untreated LNCaP and PrEC
biological duplicates was reverse transcribed with pools of
miRNA specific RT-primers, and the resultant cDNA was
subjected to real-time reverse transcription quantitative
(qRT)-PCR using specific forward primers and TaqMan
®
fluorescent probes in an array format. RNU48 was selected
as the most reliable control for expression normalization.
Initial analyses were performed using SDS software
(Applied Biosystems). Statistical tests for changes in
expression (via Cts) were performed using moderated
t-tests without multiple testing corrections using the
R limma package [29]. Mature miRNAs were deemed
differentially expressed in LNCaP compared to PrEC at
p <0.05 and fold change of ≥1.5.
Expression Tiling Arrays
Total RNA (6 μg) from untreated LNCaP and PrEC dupli-
cates was reverse transcribed with random primers and
aminoallyl- conjugated dUTP. cDNA products were preci-
pitated and resuspended with mono-reactive Cy3/5 dye (GE
Healthcare, UK), and the products were purified with Fair-
play columns (Stratagene, TX, USA). Labeling efficiency
was determined spectrophotometrically. Hybridizations for
untreated LNCaP and PrEC were repeated in two formats
to test a method to minimize probe GC bias: competitive
hybridization with fluorescently labeled gDNA in the Cy5
channel, and in a dye swap arrangement. The biological
repeats were highly reproducible (Pearson correlations:
LNCaP 0.94 and PrEC 0.96) and co-hybridization showed
no correction to probe binding efficiency (data not shown).
Tiling Array MeDIP-chip/H3K9Ac-ChIP-chip
MeDIP
4 μg of genomic DNA from untreated LNCaP and PrEC
biological duplicates was sonicated, then denatured fol-
lowed by incubation with Anti-5-Methylcytosine antibody
(Calibiochem) overnight at 4°C. The antibody/DNA com-
plexes were affinity purified using protein A/G agarose
beads (Santa Cruz Biotechnology). Products were washed,
eluted and ethanol precipitated. Efficiency of immunopre-
cipitation was confirmed by PCR at three loci; centromeric
chromosome 16, GSTP1 and GAPDH, and compared with
no-antibody and input controls, as described previously
[30]. Biological duplicates were highly reproducible
(Pearson correlation: LNCaP and PrEC 0.96).
H3K9Ac ChIP
LNCaP and PrEC cells were formaldehyde fixed in dupli-
cate prior to SDS lysis and sonication. Immunoprecipita-
tion (IP) was performed overnight at 4°C with an anti-
acetyl H3K9 antibody (Millipore, CA, USA). DNA was
eluted with 0.1M NaHCO3, 1% SDS elution buffer and
reverse cross-linked. IPs and input controls were purified
by phenol chloroform extraction and ethanol precipitation,
as described previously [31], duplicate IP reactions were
then pooled to ensure sufficient material for array analysis.
IP DNA from MeDIP and H3K9Ac were labeled as per
the manufacturers protocol (NimbleGen, WI, USA).
Briefly, 1 μg IP or input DNA was labeled with Cy-dye
random nonamers (Trilink Biotechnologies, CA, USA)
using Klenow fragment (New England Biolabs, MA, USA),
precipitated, and resuspended in hybridization buffer.
Tiling Arrays
We designed probes for 384 K feature tiling arrays (Nimble-
Gen) to cover the positive strand for the following genomic
regions: all human miRNAs listed in mirBASE v12.0 +/-
2000 bp; HOX A,B,C and D gene clusters; the chromo-
some 14 Dlk1 - Dio3 - miRNA cluster region; and hybridi-
zation control regions. Array hybridization was performed
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buffer and alignment oligonucleotides (NimbleGen). Arrays
were washed as per the manufacturers protocol and
scanned using a GenePix 4000B scanner (Molecular
Devices, CA, USA). To screen for miRNA loci that were
significantly changed between LNCaP and PrEC cells, we
fitted a linear model to the quantile-normalized probe-level
data for all probes within 500 bp of the center of a miRNA
gene. From the linear model fit, the effect of interest is the
average change between PrEC and LNCaP across all probes,
after adjusting for probe-specific effects. The t-statistics
shown in Table 1 represent the significance of this average
difference for each miRNA. MiRNAs were deemed statisti-
cally significant using a t-statistic cutoff of ≤-2 or ≥2. Venn
diagrams were drawn using Venny [32], and restricted to
overlaps for those miRNAs analysed by TLDA. Results of
all array experiments are listed in Additional file 2.
Pri-miRNA Real-Time PCR
We used Applied Biosystems pri-miRNA stem-loop spe-
cific TaqMan assays to quantify pri-miRNAs, as per the
manufacturers protocol. Briefly, first-strand cDNA was
synthesized using 10 ng DNase (RNase free DNase, Qia-
gen) treated total RNA, or no-template controls, and
Superscript reverse transcriptase (Invitrogen). Real-time
PCR reactions for each miRNA (10 μl volume) included
4 μl of RT product, were performed in triplicate and
included no-template and PCR controls using an
ABI7900 PCR system (Applied Biosystems). Reactions
performed under the following conditions: 95°C for 10
minutes, followed by 40 cycles at 95°C for 15 seconds
and 60°C for 1 minute. Relative quantitative levels of
individual miRNAs were determined using 18S for nor-
malization, and statistically significant differences were
analysed using the students t-test.
Additional material
Additional file 1: Table S1: MiRNAs showing non-canonical
epigenetic regulation. Table listing miRNA loci and genes showing
significant non-canonical epigenetic regulation. Values are expressed as
changes in LNCaP relative to PrEC. Tiling array t-statistics represent the
significance of the average difference for each miRNA, with increasing
value indicating more significant change. Mature miRNA levels are given
as fold change with the associated p-value. Chr: Chromosome, Str:
Strand, meth: DNA-methylation, L: LNCaP, P: PrEC, 5Aza: treatment with
5-Aza-CdR, p *: p-value <0.05, Epi./Cancer: publication indicating
epigenetic/cancer regulation. Chr14 cluster data includes: MIR127, MIR323,
MIR376a-2, MIR432, MIR376a-1, MIR654, MIR382, MIR487b, MIR134, MIR487b,
and MIR411.
Additional file 2: Figure S1: Validation of DNA methylation in
selected miRNA loci. Analysis of published DNA methylation
enrichment data at selected miRNA loci from Robinson et al. [11]. Graph
displays absolute number of MBDCap high throughput sequencing reads
within 300 bp of the miRNA locus.
Abbreviations
miRNA: microRNA; TLDA: TaqMan Low Density Array; ChIP: Chromatin
Immunoprecipitation; bp: base pairs; 5-Aza-CdR: 5-Aza-2’-deoxycytidine; IP:
immunoprecipitation.
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